Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol Off J Eur Soc Med Oncol, vol.28, issue.suppl_4, pp.52-61, 2017. ,
Revised international staging system for multiple myeloma: a report from international myeloma working group, J Clin Oncol Off J Am Soc Clin Oncol, vol.33, pp.2863-2872, 2015. ,
Improved survival in multiple myeloma and the impact of novel therapies, Blood, vol.111, pp.2516-2536, 2008. ,
Multiple myeloma: from front-line to relapsed therapies, Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Meet, vol.2015, pp.504-515 ,
Monoclonal antibody therapy in multiple myeloma, Leukemia, vol.31, pp.1039-1086, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01795709
Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma, N Engl J Med, vol.380, pp.1726-1763, 2019. ,
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study, 2017. ,
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing, N Engl J Med, vol.366, pp.883-92, 2012. ,
Value and cost of myeloma therapy-we can afford it, Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet, pp.647-55, 2018. ,
Haematological cancer and quality of life: a systematic literature review, Blood Cancer J, vol.5, p.305, 2015. ,
International myeloma working group updated criteria for the diagnosis of multiple myeloma, Lancet Oncol, vol.15, pp.538-586, 2014. ,
SF-36 health survey update, Spine, vol.25, pp.3130-3139, 2000. ,
, EuroQol--a new facility for the measurement of healthrelated quality of life, Health Policy Amst Neth, vol.16, pp.199-208, 1990.
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01631468
PRIMA1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance, Blood, vol.124, pp.1626-1662, 2014. ,
Highly parallel genome-wide expression profiling of individual cells using Nanoliter droplets, Cell, vol.161, pp.1202-1216, 2015. ,
BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment, Blood, 2018. ,
URL : https://hal.archives-ouvertes.fr/inserm-01900681
BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics, Leukemia, vol.30, pp.761-765, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01411102
The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma, BMC Cancer, vol.16, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01381110
International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma, Lancet Oncol, vol.17, pp.328-374, 2016. ,
Patient-reported outcome measures in the NHS: new methods for analysing and reporting EQ-5D data, Health Econ, vol.19, pp.886-905, 2010. ,
A program for missing data, J Stat Softw, vol.45, pp.1-47, 2011. ,
, Publisher's Note
, Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations